Pierre Geborek

affiliated with the university
More filtering options
  1. Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis

    Mohamed AbdGawad, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, Mårten Segelmark & Thomas Hellmark, 2009, In : APMIS. 117, p. 125-125

    Research output: Contribution to journalPublished meeting abstract

  2. Decreased Neutrophil Apoptosis in Quiescent ANCA-Associated Systemic Vasculitis.

    Mohamed AbdGawad, Åsa Pettersson, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, Lars Nilsson, Mårten Segelmark & Thomas Hellmark, 2012, In : PLoS ONE. 7, 3, e32439.

    Research output: Contribution to journalArticle

  3. Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression.

    Mohamed AbdGawad, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, L Nilsson, Mårten Segelmark & Thomas Hellmark, 2010, In : Clinical and Experimental Immunology. 161, p. 89-97

    Research output: Contribution to journalArticle

  4. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

    J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, L Coster, Pierre Geborek, Lennart Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne, V Romanus, L Klareskog & N Feltelius, 2005, In : Arthritis and Rheumatism. 52, 7, p. 1986-1992

    Research output: Contribution to journalArticle

  5. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register

    J Askling, E Baecklund, F Granath, Pierre Geborek, M. Fored, C Backlin, L Bertilsson, L Coster, L Jacobsson, S Rantapaa-Dahlqvist, Tore Saxne, R van Vollenhoven, L Klareskog & N Feltelius, 2009, In : Annals of the Rheumatic Diseases. 68, 5, p. 648-653 6 p.

    Research output: Contribution to journalArticle

  6. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

    Johan Askling, C. Michael Fored, Lena Brandt, Eva Baecklund, Lennart Bertilsson, Nils Feltelius, Lars Coster, Pierre Geborek, Lennart Jacobsson, Staffan Lindblad, Jorgen Lysholm, Solbritt Rantapaa-Dahlqvist, Tore Saxne, Ronald F. van Vollenhoven & Lars Klareskog, 2007, In : Annals of the Rheumatic Diseases. 66, 10, p. 1339-1344

    Research output: Contribution to journalArticle

  7. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

    J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelus, L Coster, Pierre Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne & L Klareskog, 2005, In : Annals of the Rheumatic Diseases. 64, 10, p. 1421-1426

    Research output: Contribution to journalArticle

  8. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

    J Askling, CM Fored, E Baecklund, L Brandt, C Backlin, A Ekbom, C Sundstrom, L Bertilsson, L Coster, Pierre Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne, L Klareskog & N Feltelius, 2005, In : Annals of the Rheumatic Diseases. 64, 10, p. 1414-1420

    Research output: Contribution to journalArticle

  9. Swedish registers to examine drug safety and clinical issues in RA

    J Askling, CM Fored, Pierre Geborek, LTH Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad & L Klareskog, 2006, In : Annals of the Rheumatic Diseases. 65, 6, p. 707-712

    Research output: Contribution to journalReview article

  10. The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice

    Eva Baecklund, Johan Askling, Lennart Bertilsson, Lars Coster, Nils Feltelius, Michael Fored, Pierre Geborek, Lennart T Jacobsson, Lars Klareskog, Staffan Lindblad, Jorgen Lysholm, Solbrutt Rantapaa-Dahlqvist, Tore Saxne & Ronald van Vollenhoven, 2008, In : Scandinavian Journal of Rheumatology. 37, Suppl. 123, p. 12-12

    Research output: Contribution to journalPublished meeting abstract

  11. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C. Kapetanovic & Tore Saxne, 2006, In : Arthritis and Rheumatism. 54, 12, p. 3782-3789

    Research output: Contribution to journalArticle

  12. Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic & Tore Saxne, 2007, In : Ugeskrift for Laeger. 169, 5, p. 420-423

    Research output: Contribution to journalArticle

  13. MR imaging of the knee in acute rheumatoid arthritis: synovial uptake of gadolinium-DOTA

    Ann G Björkengren, Pierre Geborek, Urban Rydholm, Stig Holtås & Holger Petterson, 1990, In : American Journal of Roentgenology: diagnostic imaging and related sciences . 155, 2, p. 329-332

    Research output: Contribution to journalArticle

  14. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

    Meliha C Kapetanovic, Lars Erik Kristensen, Tore Saxne, Teodora Aktas, Andreas Mörner & Pierre Geborek, 2014, In : Arthritis Research and Therapy. 16, 1, R2.

    Research output: Contribution to journalArticle

  15. Predictors of infusion reactions during infliximab treatment in patients with arthritis.

    Meliha C Kapetanovic, Lotta Larsson, Lennart Truedsson, Gunnar Sturfelt, Tore Saxne & Pierre Geborek, 2006, In : Arthritis Research and Therapy. 8, p. 1-7 R131.

    Research output: Contribution to journalArticle

  16. Hip involvement in early rheumatoid arthritis

    Kerstin Eberhardt, Eva Fex, Kjell Johnsson & Pierre Geborek, 1995, In : Annals of the Rheumatic Diseases. 54, 1, p. 45-48

    Research output: Contribution to journalArticle

  17. Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial

    Jonas K. Eriksson, Martin Neovius, Johan Bratt, Ingemar Petersson, Ronald F. van Vollenhoven, Pierre Geborek & Sofia Ernestam, 2013, In : JAMA Internal Medicine. 173, 15, p. 1407-1414

    Research output: Contribution to journalArticle

  18. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

    N Feltelius, CM Fored, P Blomqvist, L Bertilsson, Pierre Geborek, Lennart Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne & L Klareskog, 2005, In : Annals of the Rheumatic Diseases. 64, 2, p. 246-252

    Research output: Contribution to journalArticle

  19. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

    Irini Flouri, Theodora E. Markatseli, Paraskevi V. Voulgari, Kyriaki A. Boki, Ioannis Papadopoulos, Loukas Settas, Dimitrios Zisopoulos, Fotini N. Skopouli, Alexios Iliopoulos, George K. Bertsias, Pierre Geborek, Alexandros A. Drosos, Dimitrios T. Boumpas & Prodromos Sidiropoulos, 2014, In : Seminars in Arthritis and Rheumatism. 43, 4, p. 447-457

    Research output: Contribution to journalReview article

  20. Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults

    Irini Flouri, Alexandros Drosos, Kyriaki Boki, Fotini Skopouli, Dimitrios Karras, Ioannis Papadopoulos, Pierre Geborek, Symeon Panagiotakis, Dimitrois T. Boumpas & Prodromos Sidiropoulos, 2009, In : Clinical and Experimental Rheumatology. 27, 5, p. 705-706

    Research output: Contribution to journalPublished meeting abstract

  21. Measurement of oxygen and carbon dioxide partial pressures in synovial fluid after tonometry

    Pierre Geborek, B Lindoff & Sven Valind, 1988, In : Clinical Physiology. 8, 4, p. 427-432

    Research output: Contribution to journalArticle

  22. Acute alveolitis and sulphasalazine in rheumatoid arthritis

    Pierre Geborek, M Monti, F Sandblad & Frank Wollheim, 1984, In : Clinical and Experimental Rheumatology. 2, 3, p. 279-280

    Research output: Contribution to journalArticle

  23. Mononuclear cells recovered from inflammatory synovial membrane using fine-needle biopsy

    Pierre Geborek, Magnhild Sandberg Wollheim & Frank Wollheim, 1988, In : Rheumatology International. 8, 3, p. 101-105

    Research output: Contribution to journalArticle

  24. Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales

    Pierre Geborek, E Nitelius, S Noltorp, H Petri, L Jacobsson, L Larsson, Tore Saxne & I Leden, 2005, In : Annals of the Rheumatic Diseases. 64, 12, p. 1805-1807

    Research output: Contribution to journalLetter

Previous 1 2 3 Next